4//SEC Filing
Leen Ann M. 4
Accession 0001209191-23-006990
CIK 0001754068other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 5:00 PM ET
Size
17.4 KB
Accession
0001209191-23-006990
Insider Transaction Report
Form 4
Allovir, Inc.ALVR
Leen Ann M.
Chief Scientific Officer
Transactions
- Award
Common Stock
2022-07-01+14,000→ 65,256 total - Award
Stock Option (Right to Buy)
2022-01-18+56,744→ 366,344 totalExercise: $9.15Exp: 2032-01-18→ Common Stock (56,744 underlying) - Award
Stock Option (Right to Buy)
2022-07-01+26,000→ 392,344 totalExercise: $4.13Exp: 2032-07-01→ Common Stock (26,000 underlying) - Award
Common Stock
2022-01-18+23,256→ 51,256 total - Award
Common Stock
2023-02-02+43,750→ 124,006 total - Award
Stock Option (Right to Buy)
2023-02-02+81,250→ 473,594 totalExercise: $6.65Exp: 2033-02-02→ Common Stock (81,250 underlying)
Holdings
- 2,288,154(indirect: See footnote)
Common Stock
Footnotes (7)
- [F1]The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
- [F2]The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
- [F3]The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
- [F4]Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F5]25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
- [F6]25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
- [F7]25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
Documents
Issuer
Allovir, Inc.
CIK 0001754068
Entity typeother
Related Parties
1- filerCIK 0001763026
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 5:00 PM ET
- Size
- 17.4 KB